G1 Therapeutics has completed a MedImmune-backed series B round to fund development of its drug protecting bone marrow in cancer patients.
US-based G1 Therapeutics, a clinical-stage pharmaceutical company focusing on oncology, closed a series B round backed by biotechnology research company MedImmune’s corporate venturing unit at $33m yesterday.
The round was led by Eshelman Ventures and RA Capital Management, and also included Lumira Capital, Boxer Capital, which acts as a public investment fund of Tavistock Life Sciences, Hatteras Venture Partners and Mountain Group Capital.
MedImmune Ventures previously led G1’s series A round in 2013, which raised $12.5m and also featured Hatteras…
